Vascular diseases

Global Intracranial Aneurysm Market (2021 to 2028) - Share, Size, Trends, Industry Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 4, 2021

b'The "Intracranial Aneurysm Market Share, Size, Trends, Industry Analysis Report, By Type, By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global intracranial aneurysm market size is expected to reach USD 2.32 billion by 2028 according to a new study.

Key Points: 
  • b'The "Intracranial Aneurysm Market Share, Size, Trends, Industry Analysis Report, By Type, By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global intracranial aneurysm market size is expected to reach USD 2.32 billion by 2028 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.\nMarket factors favoring the market growth for intracranial aneurysm include the world\'s aging population, rising prevalence of intracranial aneurysms, sedentary and busy lifestyles, increased funding, and grant on research and innovation.
  • This large section of the population is largely contributing to the market growth.
  • As per the estimates of the BAF, in the U.S. alone, every year around 30,000 people live with brain aneurysms.

Silk Road Medical to Present at BofA Securities 2021 Virtual Health Care Conference

b'SUNNYVALE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in a fireside chat at the upcoming BofA Securities 2021 Virtual Health Care Conference.\nSilk Road Medical\xe2\x80\x99s management is scheduled to present on Wednesday, May 12, 2021 at 11:00 a.m. Eastern Time.

Key Points: 
  • b'SUNNYVALE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will be participating in a fireside chat at the upcoming BofA Securities 2021 Virtual Health Care Conference.\nSilk Road Medical\xe2\x80\x99s management is scheduled to present on Wednesday, May 12, 2021 at 11:00 a.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the presentation on the \xe2\x80\x9cInvestors\xe2\x80\x9d section of the company\xe2\x80\x99s website at: https://investors.silkroadmed.com/ .\nSilk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact.
  • The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR).
  • For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter , LinkedIn and Facebook .\n'

LeMaitre to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, April 27, 2021

b'BURLINGTON, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two investor conferences in May.\nDavid Roberts, President, is scheduled to participate in the 7th Annual Truist Securities Life Sciences Summit on Tuesday, May 4, 2021.\nHe is also scheduled to present at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021, at 9:00 AM EDT.\nLeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide.

Key Points: 
  • b'BURLINGTON, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two investor conferences in May.\nDavid Roberts, President, is scheduled to participate in the 7th Annual Truist Securities Life Sciences Summit on Tuesday, May 4, 2021.\nHe is also scheduled to present at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021, at 9:00 AM EDT.\nLeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide.
  • The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon.
  • Additional information can be found at www.lemaitre.com.\n'

InspireMD Provides Corporate Update for Shareholders

Retrieved on: 
Monday, April 19, 2021

Our business model, superior technology platform harnessed by our proprietary MicroNet embolic protection system and timing of the growth in carotid stenting have laid the foundation necessary for CGuard EPS to become a market leader in the prevention of stroke caused by carotid artery disease.

Key Points: 
  • Our business model, superior technology platform harnessed by our proprietary MicroNet embolic protection system and timing of the growth in carotid stenting have laid the foundation necessary for CGuard EPS to become a market leader in the prevention of stroke caused by carotid artery disease.
  • We believe that moving to the Nasdaq Capital Market is a strategically sound approach that places us in the company of our peers and allows for improved visibility in the market.
  • Investors and security holders are urged to read these documents free of charge on the SEC\xe2\x80\x99s web site at http://www.sec.gov.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.\n'

Global Chronic Venous Ulceration (CVU) Market Insights, Epidemiology and Market Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 22, 2021

b'The "Chronic Venous Ulceration (CVU) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis report delivers an in-depth understanding of the CVU, historical and forecasted epidemiology as well as the CVU market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.\nThe CVU market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM CVU market size from 2017 to 2030.

Key Points: 
  • b'The "Chronic Venous Ulceration (CVU) - Market Insights, Epidemiology and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis report delivers an in-depth understanding of the CVU, historical and forecasted epidemiology as well as the CVU market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.\nThe CVU market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM CVU market size from 2017 to 2030.
  • The report also covers current CVU treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.\nThe report covers the descriptive overview of Chronic Venous Ulceration (CVU), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.\nComprehensive insight has been provided into the Chronic Venous Ulceration (CVU) epidemiology and treatment.\nAdditionally, an all-inclusive account of both the current and emerging therapies for Chronic Venous Ulceration (CVU) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.\nA detailed review of Chronic Venous Ulceration (CVU) market; historical and forecasted is included in the report, covering the 7MM drug outreach.\nThe report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Chronic Venous Ulceration (CVU) market.\nIn the coming years, CVU market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.\nThe companies and academics are working to assess challenges and seek opportunities that could influence CVU R&D.
  • The therapies under development are focused on novel approaches to treat/improve the disease condition.\nThe publisher analysed gender-specific data of Venous Ulcers, which suggests that Venous Ulcers is more prevalent in females than in males.\nThe publisher has also analysed data on types of Venous Ulcers, which suggests that Acute Venous Ulcers was more common than Chronic Venous Ulcers.\nThe diagnosed prevalence of venous ulcers and venous leg ulcers was also analysed by the publisher.\nAge-specific data of Venous Ulcers suggests that prevalence of Venous Ulcers in the US, was highest in the age group of >70 years, followed by 60-70 years and

Medtronic Receives U.S. FDA Approval for Pipeline™ Flex Embolization Device with Shield Technology™

Retrieved on: 
Wednesday, April 21, 2021

b'First Patient Receives New Shield Surface Modification, An Advance in Flow Diversion Therapy, at NYU Langone Health\nDUBLIN, April 21, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for Pipeline Flex Embolization Device with Shield Technology.

Key Points: 
  • b'First Patient Receives New Shield Surface Modification, An Advance in Flow Diversion Therapy, at NYU Langone Health\nDUBLIN, April 21, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for Pipeline Flex Embolization Device with Shield Technology.
  • NYU Langone Health in New York City performed the first patient procedure in the nation with the new device.\nCelebrating its 10-year anniversary in the U.S. in 2021, Pipeline Flex Embolization Device diverts blood flow away from a brain aneurysm.
  • "\nPublished on June 1, 2020, in the Journal of NeuroInterventional Surgery (JNIS), results from the SHIELD Study (Periprocedural to 1-year safety and efficacy outcomes with the Pipeline Embolization Device with Shield technology for intracranial aneurysms: a prospective, post-market, multi-center study) demonstrate that the third-generation Pipeline Flex Embolization Device with Shield Technology continues the strong record of safety and efficacy of flow diversion therapy with the Medtronic family of products.
  • "Ten years ago, Medtronic changed the treatment paradigm in brain aneurysms with the approval of Pipeline Embolization Device, and we continue to challenge ourselves to deliver solutions that improve outcomes and increase value for all healthcare stakeholders.

Cerus Endovascular Announces IDE Approval from the U.S. FDA to Conduct Clinical Study of the Contour Neurovascular System™

Retrieved on: 
Wednesday, April 21, 2021

"The IDE study protocol closely aligns with protocols of other intra-saccular aneurysm repair devices that have received FDA approval.

Key Points: 
  • "The IDE study protocol closely aligns with protocols of other intra-saccular aneurysm repair devices that have received FDA approval.
  • Given the real-world patient outcomes we have experienced in Europe, where the Contour Neurovascular System has had CE mark approval since March 2020, we are hopeful that we will see similar, strong results from this trial.
  • "\nThe study, is designed to develop a robust data set to support the safety and efficacy of the Contour Neurovascular System for the endovascular embolization of wide-necked, bifurcated, saccular intracranial aneurysms.
  • The Company\'s CE Marked products, the Contour Neurovascular System and the Neqstent Coil Assisted Flow Diverter, expand the number and types of treatable intracranial aneurysms.

Worldwide Intracranial Aneurysm Industry to 2025 - Featuring Medtronic, B. Braun and Penumbra Among Others

Retrieved on: 
Tuesday, April 20, 2021

Amongst all, the endovascular coiling segment holds the highest market share.\nBy Condition, the market is classified as an unruptured aneurysm and Ruptured aneurysm.

Key Points: 
  • Amongst all, the endovascular coiling segment holds the highest market share.\nBy Condition, the market is classified as an unruptured aneurysm and Ruptured aneurysm.
  • Amongst all, the ruptured aneurysm segment holds the highest market share.\nBy Treatment Type, the market is classified as Medication and Surgery.
  • Amongst all, the surgery segment holds the highest market share.\nBy End-user, the market is classified as Hospital & Clinics, Diagnostic Centers, and others.
  • Amongst all, the hospital segment holds the highest market share.\nBy Geography, North America is projected to lead the market.\n1.

Long COVID Dramatically Increases Cases Of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Retrieved on: 
Monday, April 19, 2021

Anthony Fauci concurs, lasting COVID-19 effects indicative of ME/CFS.\nOrganizers believe the surge in Long COVID is driving more participation.

Key Points: 
  • Anthony Fauci concurs, lasting COVID-19 effects indicative of ME/CFS.\nOrganizers believe the surge in Long COVID is driving more participation.
  • "They have things that are highly suggestive of myalgic encephalomyelitis/chronic fatigue syndrome: brain fog, fatigue, difficulty concentrating.
  • Media is encouraged to join the live announcement at 3:00pm ET via zoom.\n"The issues brought to the forefront by Long COVID have a direct impact on our communities.
  • expanded its 2021 advocacy events to include many post-infectious chronic illness communities, such as: ME/CFS, Long COVID, Postural Orthostatic Tachycardia Syndrome (POTS), other forms of dysautonomia, Ehlers-Danlos Syndrome (EDS), Hypermobility Spectrum Disorder (HSD), and Mast Cell Activation Syndrome (MCAS).

North America Biofilms Treatment Market Report 2020-2027: Market Opportunities with Increasing Public and Private Participation in Biofilms Treatment Market

Retrieved on: 
Monday, March 22, 2021

North America Biofilms Treatment market is expected to reach US$ 951.16 million in 2027 from US$ 546.93 million in 2019.

Key Points: 
  • North America Biofilms Treatment market is expected to reach US$ 951.16 million in 2027 from US$ 546.93 million in 2019.
  • The report provides trends prevailing in the North America biofilms treatment market and the factors driving market along with those that act as hindrances.
  • Based on the wound, the North America the biofilms treatment market, is segmented into traumatic and surgical wounds, diabetic foot ulcers, pressure ulcers, venous leg ulcers, and others.
  • Smith & Nephew, MiMedx, ConvaTec Group Plc are among the leading companies operating in the North America biofilms treatment market.